No Image

Industry perspectives on prenatal genetic testing.

July 14, 2019 dna 0
Icon for Elsevier Science Related Articles

Industry perspectives on prenatal genetic testing.

Semin Perinatol. 2018 08;42(5):314-317

Authors: Swanson A, Goldberg JD

Abstract
Until recent years, prenatal genetic tests have been almost exclusively developed and implemented by academic physicians and laboratories. In the last several years, industry has led the development of novel prenatal genetic tests, funded clinical trials and implemented these tests into clinical practice. That these efforts have been driven by industry has raised questions about diagnostics development regulations, consistency in reporting of results, and management of potential conflicts of interest. In this article, these topics are addressed from an industry perspective. While commercial laboratories may have the resources to develop and offer novel genetic tests, collaboration with healthcare providers is crucial for appropriate, effective, and efficient utilization of such tests.

PMID: 30241950 [PubMed – indexed for MEDLINE]

No Image

Researchers clock DNA’s recovery time after chemotherapy

July 12, 2019 dna 0
A team of researchers found that DNA damaged by the widely used chemotherapy drug cisplatin is mostly good as new in noncancerous tissue within two circadian cycles, or two days. The results could inform the development of chronochemotherapies — strategies aimed at administering chemotherapy drugs at times that maximize tumor damage while minimizing side effects.